{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:33Z","timestamp":1791588933912,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a common, chronic, relapsing, pruritic, neuroimmune skin disease, requiring long\u2010term symptom control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The ARCADIA long\u2010term extension (LTE) study evaluates nemolizumab safety and efficacy in \u226512\u2010year\u2010old patients with moderate\u2010to\u2010severe AD up to 200\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients from previous nemolizumab AD trials (Phase 2\/3) or newly recruited adolescents with moderate\u2010to\u2010severe AD were enrolled. A background regimen of topical corticosteroids with\/without topical calcineurin inhibitors was permitted based on disease control. Long\u2010term safety was the primary endpoint. Efficacy assessments were secondary endpoints, including the proportion of patients achieving Investigator's Global Assessment (IGA) 0\/1 (clear\/almost clear), Eczema Area and Severity Index (EASI)\u201075 (75% improvement from lead\u2010in baseline in EASI), Visual Analogue Scale (VAS) Pruritus and VAS sleep loss \u22654\u2010point improvement from lead\u2010in baseline and quality of life. Observed data up to Week (W) 104 are presented for patients with previous nemolizumab experience (PNE) and no previous nemolizumab experience (NNE) at LTE baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At interim analysis data cut\u2010off (21 July 2024), 1062 of 1901 patients completed W104. Exposure to nemolizumab in this study was equal across cohorts. The majority (92.6%) of treatment\u2010emergent adverse events (TEAEs) were mild\/moderate in severity; only 22.1% were considered related to nemolizumab. The most common (\u22655.0%) TEAEs were COVID\u201019 (19.6%), nasopharyngitis (19.5%), atopic dermatitis (18.1%), upper respiratory tract infection (12.7%), headache (6.5%) and asthma (5.5%). At LTE baseline, the proportion of PNE and NNE patients was IGA 0\/1: 27.1% and 17.1%; EASI\u201075: 38.8% and 25.8%; VAS Pruritus \u22654\u2010point improvement: 58.7% and 31.6%; and VAS sleep loss \u22654\u2010point improvement: 52.9% and 31.6%, respectively. At W104, this proportion was IGA 0\/1: 62.6% and 58.2%; EASI\u201075: 88.2% and 85.4%; VAS Pruritus \u22654\u2010point improvement: 87.2% and 82.0%; and VAS sleep loss \u22654\u2010point improvement: 70.8% and 68.9%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuous nemolizumab treatment was well\u2010tolerated through W104 with clinically meaningful improvements in AD signs and symptoms and patient\u2010reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      NCT03989206:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/search?term=NCT03989206\">https:\/\/clinicaltrials.gov\/search?term=NCT03989206<\/jats:ext-link>\n                      ; EUDRACT number: 2019\u2013001889\u201015. Data available upon request:\n                      <jats:email>clinical.studies@galderma.com<\/jats:email>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70080","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:56:39Z","timestamp":1760406999000},"page":"841-855","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of nemolizumab for atopic dermatitis up to 2\u2009years in open\u2010label extension study"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6245-7442","authenticated-orcid":false,"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology Lyon Sud Hospital, Hospices Civils de Lyon, Inserm U1111 Centre International de Recherche en Infectiology  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sidbury","sequence":"additional","affiliation":[{"name":"Seattle Children's Hospital  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences  Washington, DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research  Waterloo Ontario Canada"},{"name":"Division of Dermatology, Temerty Faculty of Medicine, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Medicine University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"De Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Utrecht University\/UMC Utrecht  Utrecht Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Rzesz\u00f3w  Rzesz\u00f3w Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Department of Dermatology Catholic University of the Sacred Heart  Milan Italy"},{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Barber","sequence":"additional","affiliation":[{"name":"Prof., Kirk Barber Research  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"Galus","sequence":"additional","affiliation":[{"name":"Synexus Polska Sp. z o.o. Oddzial w  Warszawa Poland"},{"name":"Department of Histology and Embryology Medical University of Warsaw  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kaszuba","sequence":"additional","affiliation":[{"name":"\u201cDERMED\u201d Centrum Medyczne, Sp. z o.o.  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zirwas","sequence":"additional","affiliation":[{"name":"DOCS Dermatology  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Nahm","sequence":"additional","affiliation":[{"name":"University of California, San Diego School of Medicine  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretel","family":"Trullenque","sequence":"additional","affiliation":[{"name":"Floridian Research Institute, LLC  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Maintz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Bonn  Germany"},{"name":"Venusberg\u2010Campus 1  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sady","family":"Alpizar","sequence":"additional","affiliation":[{"name":"Clinical Research Trials of Florida, Inc.  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wook","family":"Son","sequence":"additional","affiliation":[{"name":"Korea University Ansan Hospital  Ansan\u2010si Gyeonggi\u2010do Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[{"name":"First OC Dermatology Research  Fountain Valley California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-1605","authenticated-orcid":false,"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Medical Center, New Center One, Dermatology Research  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yeon","family":"Cheong","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ryzhkova","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Drahos","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Ulianov","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2478","authenticated-orcid":false,"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.10271"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.028"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.05.007"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3511"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.010"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-64804-0_2"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061602"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.530"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.337"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.02.017"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.009"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.005"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00527-x"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.5534"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_2_14_22_1","unstructured":"DUPIXENT (Dupilumab) Prescribing Information.2024."},{"key":"e_1_2_14_23_1","unstructured":"ADBRY (tralokinumab\u2010ldrm) Prescribing Information.2021."},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.01.020"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1655137"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.29015.jsi"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15919"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639097"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.004"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14791"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.02.009"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.013"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17218"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01203-0"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.019"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70080","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:23:38Z","timestamp":1777533818000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jdv.70080"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70080","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"2025-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}